Finance Watch: Four New IPOs Hold Steady In First Days Of Trading
Sarepta, Relay, Bicycle, Crinetics Launch Large Follow-Ons
Public Company Edition: Xilio, Ventyx, MiNK and Context went public in the US and later traded at or above their initial public offering prices. Also, Sarepta raised $500m and Relay grossed $350m in new offerings, while Oncopeptides, Esperion, Zymergen and Ardelyx reorganized and cut jobs.
You may also be interested in...
As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.
The company claims its synthetic biology technology will revolutionize manufacturing but its share have dipped after the fraud allegations.
With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.